Market Place
Sourcing Support
Obesity drugs don`t make WHO`s essential list, but Ebola, MS drugs added
27 Jul 2023 //
REUTERS
Teva`s Generic Naltrexone Receives Approval in the U.S.
06 Jul 2023 //
FDA
JanOne files international patent appl. for methods of using low dose naltrexone
28 Jun 2023 //
PR NEWSWIRE
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104
13 Oct 2022 //
GLOBENEWSWIRE
Opiant Pharma completes enrollment in phase 2 trial of OPNT002
08 Oct 2022 //
PHARMABIZ
Opiant Announces Completion of Enrollment in Ph 2 Trial of OPNT002, Naltrexone
06 Oct 2022 //
GLOBENEWSWIRE
BioCorRx Begins Dosing in PI Trial of BICX104 for Opioid Use Disorder
30 Jun 2022 //
GLOBENEWSWIRE
Delpor Begins Dosing in PI Trial of Once or Twice-Yearly Naltrexone Implant
28 Apr 2022 //
BUSINESSWIRE
Statera Biopharma and Immune Therapeutics Announce Strategic Agreement
27 Apr 2022 //
GLOBENEWSWIRE
Opiant Pharma Begins Dosing in Phase 2 Trial of OPNT002 for Alcohol Use Disorder
20 Jan 2022 //
GLOBENEWSWIRE
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
22 Sep 2021 //
GLOBENEWSWIRE
Low Dose Naltrexone Being Studied as Treatment for CRPS
19 Sep 2021 //
PAINNEWSNETWORK
FDA Grants Orphan Drug Status to Soin Therapeutics for Low Dose Naltrexone
08 Sep 2021 //
PRNEWSWIRE
Campbell Spin Off of Therapeutic Solutions using Naltrexone
16 Jun 2021 //
PRNEWSWIRE
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus
14 Jan 2021 //
PRNEWSWIRE
Enforcement Report - Week of February 5, 2020
05 Feb 2020 //
FDA
Enforcement Report - Week of October 9, 2019
09 Oct 2019 //
FDA
Wistar secures funds for clinical studies on opioid use in HIV patients
27 Sep 2019 //
CLINICALTRIALSARENA
Enforcement Report - Week of September 4, 2019
04 Sep 2019 //
FDA
Naltrexone/bupropion (Mysimba) risk of adverse reactions affect ability to drive
19 Aug 2019 //
GOVUK
Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
29 Jul 2019 //
PR NEWSWIRE
Indivior wins fresh hold on Dr. Reddy`s Suboxone copy
12 Dec 2018 //
REUTERS
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
11 Sep 2018 //
FORBES
Enforcement Report - Week of April 25, 2018
25 Apr 2018 //
FDA
Trump opioid plan writes in favoritism to single company’s addiction medication
26 Mar 2018 //
STAT NEWS
Indivior loses patent battle with generics maker Alvogen
24 Mar 2018 //
ENDPTS
How America’s prisons are fueling the opioid epidemic
14 Mar 2018 //
VOX
FDA to boost drug therapy for addicts
26 Feb 2018 //
NWA ONLINE
Final NHS ‘no’ for obesity pill Mysimba
12 Dec 2017 //
PHARMA TIMES
NICE bars obesity pill from routine NHS use
31 Jul 2017 //
PHARMA TIMES
Elite halts trials of reformulated SequestOx after BE data falls short
10 Jul 2017 //
IN PHARMATECHNOLOGIST
All Scientific Hands on Deck to End the Opioid Crisis
01 Jun 2017 //
DIRECTOS BLOG
NICE rejects Orexigen’s weight-loss pill
05 May 2017 //
PHARMA TIMES
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
17 Apr 2017 //
GLOBENEWSWIRE
Pfizer’s abuse-deterrent opioid bags US nod
22 Aug 2016 //
PHARMATIMES
Naltrexone Diminishes Opioid Relapse Rates In Ex-Convicts
31 Mar 2016 //
FORBES
French drug developer Pharnext to take rare approach to pricing
17 Dec 2015 //
ET HEALTHWORLD
Future obesity drugs must provide improved efficacy & safety,says GBI Research
17 Dec 2015 //
CPHI-ONLINE
Orexigen`s Mysimba (Naltrexone / Bupropion) Approved in Europe For Obesity
18 Apr 2015 //
EMA
Europe Approves Orexigen`s Weight-Loss Pill Mysimba
26 Mar 2015 //
PHARMATIMES
Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
23 Jan 2015 //
PR NEWSWIRE
First Stem-Cell Therapy Recommended For Approval in EU
19 Dec 2014 //
